Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 09/27 05:30:12 pm
78.1 CHF   +0.13%
07:16a NOVARTIS : Sandoz invites young entrepreneurs to enter Sandoz HACk, ..
09/27 XENCOR : grows in San Diego
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2012 | 06:55pm CEST

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
07:16a NOVARTIS : Sandoz invites young entrepreneurs to enter Sandoz HACk, a global com..
09/27 XENCOR : grows in San Diego
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/26 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/26 NOVARTIS : Nouscom Appoints New Chief Operating Officer and Strengthens the Boar..
09/23 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/23 NOVARTIS : Alcon Research Assigned Patent
09/23 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/22 DOES NOVARTIS AG (NYSE : NVS) Have The Solution For Malaria?
09/22 NOVARTIS : Pharma star celebrates two special anniversaries
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/27 Kite Flies, But Durability Remains The Key Unknown
09/26 Array Plays Catch-Up In Braf-Mek Derby
09/26 BIOTECH FORUM DAILY DIGEST : Behind Some Big Moves In Small Caps. Spotlight On V..
09/26 Array Bio's encorafenib-binimetinib combo successful in late-stage melanoma s..
09/23 FDA OKs three new uses for Novartis' Ilaris
Advertisement
Financials ($)
Sales 2016 48 892 M
EBIT 2016 11 365 M
Net income 2016 7 821 M
Debt 2016 14 753 M
Yield 2016 3,53%
P/E ratio 2016 23,28
P/E ratio 2017 21,29
EV / Sales 2016 4,63x
EV / Sales 2017 4,50x
Capitalization 211 785 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 89,9 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.14%211 231
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
GLAXOSMITHKLINE PLC19.26%103 357
More Results